Royalty Report: Drugs, Central Nervous System, Stroke treatment – Collection: 369272

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Central Nervous System
  • Stroke treatment
  • Disease
  • cardiac
  • Delivery
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369272

License Grant
University hereby grants to Licensee the world-wide right and license to the Patent Rights set forth to the full end of the term of each patent included therein unless sooner terminated as hereinafter provided. This grant is expressly subject to the rights of the U.S. Government, if any.

In order to establish a period of exclusivity for Licensee, University hereby agrees that it shall not grant any other license to make, have made, use, lease and sell the Patent Rights during the period of time commencing with the Effective Date of this Agreement and terminating with the full end of the term of this Agreement, unless sooner terminated as hereinafter provided.

Licensee shall have the right to sublicense worldwide any of the rights, privileges and license granted hereunder.

License Property
Patent Rights' shall mean

5,616,707 – Compounds which are useful for prevention and treatment of central nervous system disorders

5,726,316 – Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Field of Use
Ispronicline (TC-1734). Ispronicline is a novel small molecule that we are developing as an oral treatment for conditions marked by cognitive impairment that afflict elderly persons, including Alzheimer’s disease and age associated memory impairment, commonly referred to as AAMI

Field of use is for nicotinic compounds for use in therapeutic applications, including for prevention and treatment of central nervous system disorders.

IPSCIO Record ID: 369274

License Grant
Licensor, a nonprofit organization supporting research on the causes of, and treatments for, schizophrenia and bipolar disorder,  hereby grants to Licensee a perpetual, irrevocable, worldwide exclusive license (with the right to sublicense) to any and all Development Program Inventions (including, without limitation, those assigned to Licensor by Licensee) for all purposes. In addition, Licensor expressly agrees that Licensee may use, disclose and reference any and all such Development Program Results in any manner whatsoever and that such rights are perpetual and irrevocable. Notwithstanding the foregoing, Licensor reserves the right to use such Development Program Inventions and Development Program Results only for its own internal, non-profit, non-commercial, administrative purposes or as expressly permitted by agreement and for no other purposes whatsoever.

License Grant shall mean an exclusive license (with the right to grant sublicenses) under Licensee Proprietary Information that (i) Licensee owns or licenses (with the right to further sublicense) as of the date of grant, except that such license would be non-exclusive with respect to Licensee Proprietary Information that are not patent rights, and (ii) is necessary to develop, make, use, sell, offer for sale or import the Compound in the United States, Europe or Japan, as the case may be, to develop, make, use, sell, offer for sale and import the Compound in the United States, Europe or Japan, as the case may be.

License Property
Licensor, a medical research institute, is the world’s leading nonprofit organization that supports research on the causes and treatment of schizophrenia and bipolar disorder, through its own laboratory and support of researchers worldwide and desires to support the further development and commercialization of the Compound (as defined below) in order to accelerate the introduction of a novel therapy for the benefit of schizophrenia patients worldwide.

Compound shall mean the compound known by Licensee as TC-1827 and its salts.

Field of Use
TC-1827 is a proprietary compound  for the treatment of the cognitive impairment associated with schizophrenia.

Field of use is for the treatment of diseases and disorders of the central nervous system, including schizophrenia.

IPSCIO Record ID: 303746

License Grant
The parties entered into an exclusive worldwide license agreement to develop and commercialize V158866, a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.
License Property
V158866 is for post-traumatic stress disorder and other central nervous system diseases.  V158866 is a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.

Field of Use
Licensee will utilize the inhibitor, V158866, for post-traumatic stress disorder and other central nervous system diseases.

Licensee is a biopharmaceutical company committed to developing treatments for psychiatric disorders.

IPSCIO Record ID: 245927

License Grant
Licensor, a University, hereby grants to Company and its affiliates for the term (a) a royalty-bearing license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the field in the territory and to develop and perform Licensed Processes in the field in the territory;  (b) a royalty-bearing license to use the tangible property to develop, make, have made, use, sell, offer to sell, lease and import Licensed Products in the field in the territory and to develop and perform Licensed Processes in the field in the territory.
License Property
Patent Rights shall mean (a) the United States and international patents listed.
US Patent Application #10/108,195 titled Methods and Products related to FGF Dimerization.

Licensed Process shall mean any process that, absent the license granted hereunder, would infringe one or more valid claims of the Patent Rights or which uses a Licensed Product.

United States Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'

International (non-U.S.) Patents and Applications
M.I.T. Case No. 9265
'A Novel Fibroblast Growth Factor Dimer'

WO Patent Application Serial No US02/09517, Filed on March 27, 2002
Entitled METHODS AND PRODUCTS RELATED TO FGF DIMERIZATION

Field of Use
Field shall mean human therapeutics for the treatment of neurological disorders and conditions, which shall include disorders and conditions pertaining to the central nervous, peripheral nervous, autonomic nervous, and neuromuscular systems.

patents pertain to a novel molecule for treatment of neurological disorders, including stroke.

IPSCIO Record ID: 376935

License Grant
University has granted to the Licensee a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Licensee is required to use commercially reasonable efforts to develop, manufacture and sell products (Licensed Products) in the Licensed Field of Use (as defined) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement.
License Property
Bryostatin structural derivatives, known as “bryologs' is an active pharmaceutical ingredient to be used in a drug product.
Field of Use
Field of use is for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury.

IPSCIO Record ID: 299252

License Grant
Licensor, a medical college, hereby grants Licensee an exclusive right and license to Licensor’s rights to make, use, and Sell Licensed Products for the Field of Use in the Licensed Territory during the term of this Agreement.
License Property
Licensed Product(s) shall mean any process, service, or product, the manufacture, use, or sale of which is covered by a Valid Claim or incorporates or uses any Licensed Technology.

Licensed Technology shall mean all information and materials proprietary to Licensor, including designs, technical information, know how, knowledge, data, specifications, test results and other information relating to the Licensed Patents and disclosed by Licensor to Licensee on the date of this Agreement or during the term hereof.

Licensed Patents shall mean the inventions embodied in the patent applications and patents identified in hereof, together with all divisionals, continuations, reissues, and foreign counterparts of such applications or patents.

Licensor holds certain title and rights in a joint invention on the alpha 7 nicotinic receptor agonists and the JAK pathway with Licensee, specifically

Case #016-02 'Methods and Compositions for Treatment of Central Nervous System Disorders'
Patent Status Provisional U.S. patent application prepared by Licensee, complete with data and claims.

Field of Use
License relates to a patent covering a method of use of a substance that stimulates the activity of nicotinic acetylcholine receptors by inhibiting the activity of another class of receptors, a method of use of increasing the presence of a therapeutic substance to treat neurodegeneration and a screening method.

Neurodegeneration refers to the progressive atrophy and loss of function of neurons, which is present in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

IPSCIO Record ID: 367292

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license, with the right to grant sub-licenses solely pursuant to Agreement, in the Licensor Intellectual Property Rights and the Licensor Licensed Product identified in the Notice Letter dated March 14, 2007 to develop, have developed, make, have made, use, have used, sell, have sold and offer for sale the Licensor Licensed Product in the Field anywhere in the Territory.
License Property
Licensed Product as used herein shall mean molindone and it salts, racemic mixtures, isomers, derivatives, and analogues thereof as licensed to Licensee in accordance with the terms and conditions of this Agreement.

Patent Rights
6,897,212 – Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones
6,613,763 – Use of molindone to treat oppositional defiant disorder and conduct disorder

Field of Use
Field shall mean for the treatment, diagnosis or prevention of central nervous system related diseases and indications in humans and animals.

IPSCIO Record ID: 315667

License Grant
The Swiss Licensee obtained a worldwide, sub-licensable license from the Licensor covering four different compounds, which included Mazindol (the “Licensed Compounds”). Under the Second Amendment it was agreed to include sales realized upon the commercialization of products developed on the basis of the Licensed Compounds during the terms of their respective patents.  The Licensee’s majority shareholders are also majority shareholders in the Licensor and as such are considered to be related parties.
License Property
Licensed Compound, Mazindol, is an active molecule in a proprietary controlled release formulation. The controlled-release formulations are being designed to optimize their pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long acting symptom control and designed to uniquely meet the needs of patients.

Licensor is primarily focusing on the repurposing of safe and (cost-)effective compounds to treat Attention Deficit/HyperActivity Disorder (ADHD), sleep disorders and cognitive impairment.

Field of Use
Licensee will utilize Mazindol, an active substance, to cover a range of areas including the therapeutic use of mazindol for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and combination therapies containing mazindol (add-ons with iron or stimulants) as well as sleep disorders such as narcolepsy or idiopathic hypersomnia.  Attention Deficit Hyperactivity Disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness.

Licensee is an innovative biotechnology company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, or ADHD. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders.

IPSCIO Record ID: 369401

License Grant
Licensor shall, and hereby does, grant to Swedish Licensee, with effect on the Effective Date, an exclusive (even as to Licensor and its Affiliates), royalty-bearing, worldwide license, with the right to grant sublicenses, under Licensor Technology and Licensor Patent Rights and Licensor’s interest in Joint Technology and Joint Patent Rights
(a) to Exploit (i) Ispronicline and Ispronicline Products (including conducting the Pre-Phase IIb Program), (ii) any Licensed Derivatives with respect to Ispronicline, and (iii) any Additional Compounds with respect to the foregoing;
(b) to Exploit (i) Collaboration Candidates and Active+ Compounds until such time, with respect to each such Collaboration Candidate and Active+ Compound, as it becomes a Terminated Compound, (ii) Collaboration Compounds, Candidate Drugs, and Products (other than Ispronicline or Ispronicline Products (or any Licensed Derivatives with respect thereto), Option Compound Candidate Drugs or Option Compound Products), and (iii) any Additional Compounds with respect to the foregoing; and
(c) to Exploit (i) Option Compound Candidate Drugs and Option Compound Products and (ii) any Additional Compounds with respect to the foregoing;
License Property
Ispronicline means (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-pentene-2-amine, identified by the compound structure set forth in agreement and also identified as TC-1734 in U.S IND 69,110, including any salt form, polymorph, crystalline form, hydrate, solvate or formulation thereof.

Product means a product that consists of or contains a Candidate Drug as an active ingredient.

Candidate Drug means each of (a) Ispronicline, (b) each Active+ Compound that is not a Terminated Compound, (c) each Collaboration Compound for which Licensee commences GLP Toxicology Studies as provided in Agreement or for which Licensee does not commence GLP Toxicology Studies but Initiates a Clinical Trial, (d) each Option Compound for which Licensee exercises an Option, (e) each Licensed Derivative with respect to (i) any such Option Compound made by or on behalf of Licensee or its Affiliates or Sublicensees or (ii) Ispronicline or any such Active+ Compound or Collaboration Compound made by or on behalf of (A) Licensee, Licensor or any of their respective Affiliates or Sublicensees during the Research Program Term or the Tail Period or (B) Licensee, or its Affiliates or Sublicensees after the Tail Period and (f) in each case ((a) through (e)), any salt form, polymorph, crystalline form, hydrate, solvate or formulation thereof.

Compound means any compound Controlled by Licensor.

Licensor Patent Rights means any Patent Rights Controlled by Licensor or its Affiliates that contain one or more claims that cover (a) Licensor Technology, (b) any (i) Collaboration Candidate, Active+ Compound, Collaboration Compound, Candidate Drug or Product, (ii) Additional Compound or Derivative with respect to any of the foregoing, or (iii) product that contains any of the foregoing (including any Additional Product) or (c) the Exploitation of any of the foregoing ((a) and (b)) in the Field or in Schizophrenia.

Compound Family means (a) with respect to each Lead Collaboration Compound, such Lead Collaboration Compound, all Related Collaboration Compounds with respect to such Lead Collaboration Compound, and all Licensed Derivatives with respect to either of the foregoing, (b) with respect to Ispronicline, Ispronicline and all Licensed Derivatives with respect thereto, (c) with respect to each IND-Ready Option Candidate Drug, such IND-Ready Option Candidate Drug and all Licensed Derivatives with respect thereto and (d) with respect to each POC Option Candidate Drug, such POC Option Candidate Drug and all Licensed Derivatives with respect thereto.

Lead Collaboration Compound means each Active+ Compound that is selected by the JRC or Licensee, as a Lead Collaboration Compound during the Research Program Term or the Tail Period, including any salt form, polymorph, crystalline form, hydrate, solvate or formulation thereof. Notwithstanding anything in this Agreement to the contrary, in no event shall a Licensed Derivative with respect to Ispronicline be a Lead Collaboration Compound unless Licensee, designates it as a Lead Collaboration Compound pursuant to this agreement. For purposes of clarity, Ispronicline is not a Lead Collaboration Compound and, except as provided in the preceding sentence, Licensed Derivatives with respect to Ispronicline, even if Derived during the Research Program Term or the Tail Period, are not Lead Collaboration Compounds.

Option Compound means during the Option Term (and, if an IND-Ready Option Period or POC Option Period begins during the Option Term and has not expired as of the last day of the Option Term, thereafter until the last day of such IND-Ready Option Period or POC Option Period), any Secondary Pharmacology Compound or Other NNR Compound on which Licensor conducts research or development activities specifically for use in the Territory in the Field or, prior to the Schizophrenia Expiration Date, Schizophrenia and elects, in its sole discretion, to designate as an Option Compound. For purposes of clarity, (a) an Alpha4Beta2 Agonist shall not be an Option Compound, (b) an Unexercised Option Compound shall, upon becoming an Unexercised Option Compound, cease to be an Option Compound, (c) a Terminated Compound that was previously an Option Compound shall, upon becoming a Terminated Compound, cease to be an Option Compound and (d) an Excluded Zone Compound shall not be an Option Compound.

Ispronicline Product means any Product that contains Ispronicline as an active ingredient. For purposes of clarity, an Ispronicline Product is also a Product.

Field of Use
Licensee plans to continue development of AZD3480 (TC-1734) in Alzheimer's disease and cognitive deficits in schizophrenia.

Field means the treatment, prevention or diagnosis of Primary Indications and Small Market Indications in humans or animals including Schizophrenia.

Schizophrenia means a condition having the diagnostic criteria for schizophrenia identified in DSM-IV, ICD-10 or any other Diagnostic Manual, but excluding CDS. When used as reference to a field (as distinguished from an indication), Schizophrenia means the treatment, prevention or diagnosis of such a condition.

Small Market Indication means each of the following (a) Vascular Dementia; (b) Dementia due to HIV; (c) Dementia due to head trauma; (d) Dementia due to Parkinson’s disease; (e) Dementia due to Huntington’s disease; (f) Dementia due to Pick’s disease; and (g) Dementia due to Creutzfeldt-Jakob disease; (h) Dementia due to other general medical conditions (including Dementia with Lewy Bodies); (i) substance induced Dementia; (j) Dementia due to multiple etiologies; in each case ((a) through (j)) based on diagnostic criteria included in DSM-IV, ICD-10 or any other Diagnostic Manual; (k) any Newly-Defined Cognitive Disorder or Associated Cognitive Impairment; provided that, in the case of (h) through (k), only if such Dementia, Newly-Defined Cognitive Disorder or Associated Cognitive Impairment has a patient population in the United States of 200,000 or less based on the findings of such pharmaceutical market research organization(s) as Licensee may designate from time to time with Licensor’s consent, not to be unreasonably withheld, conditioned or delayed; and (l) any Additional Small Market Indication. For purposes of clarity, Schizophrenia is not a Small Market Indication.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.